Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality

Journal of Diabetes Investigation

Volumn 7, Issue 5, 2016, Pages 674-676

  Shimoda, Masashi ^a   Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SULFONYLUREA DERIVATIVE;

ADULT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ELECTRONIC MEDICAL RECORD; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MALE; MORTALITY; NON FATAL MYOCARDIAL INFARCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REGISTERED NURSE; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; UNITED STATES;

EID: 84991113244     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12494     Document Type: Note

References (5)

1. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes V. Evaluation of phenformin therapy. Diabetes 1975; 24: 65–184.
2. Li Y, Hu Y, Ley SH, et al. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care 2014; 37: 3106–3113.
3. Zeller M, Danchin N, Simon D, et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95: 4993–5002.
4. Klamann A, Sarfert P, Launhardt V, et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000; 21: 220–229.
5. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013; 10: 289–301.